touchPODCAST-logo

touchPODCAST

0 Favorites

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to...

Location:

United States

Description:

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

Language:

English


Episodes
Ask host to enable sharing for playback control

Exploring all angles: Neuroprotective strategies beyond IOP in primary and steroid-induced open-angle glaucoma

3/30/2026
touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen to a series of interviews with Dr Maria-João Menéres who will provide her expert insights into the mechanisms of retinal ganglion cell (RGC) damage in both primary open-angle and secondary, steroid-induced glaucoma, and the importance of neuroprotection to mitigate the risk of glaucoma development or progression. The expert: This touchPODCAST is for HCPs in Portugal only. This activity is funded by an independent medical education grant from Alimera Sciences Europe Limited. The activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchOPHTHALMOLOGY.com

Duration:00:28:10

Ask host to enable sharing for playback control

Optimizing presbyopia-correcting IOL selection and patient expectations

3/23/2026
touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen as Prof. Sumit (Sam) Garg shares expert clinical insights on how AI-supported biometric analysis can increase refractive accuracy and support confident presbyopia-correcting IOL selection, including which patient and ocular characteristics are most likely to benefit from AI-based tools. He also outlines practical strategies for structuring preoperative counselling to set realistic expectations and improve patient satisfaction through clear, effective communication. The expert: This touchPODCAST is for HCPs outside of the UK. This educational activity is funded by an independent medical education grant from Johnson & Johnson Surgical Vision, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchophthalmology.org

Duration:00:15:41

Ask host to enable sharing for playback control

Advancing outcomes in CP-CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management

3/20/2026
touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY Listen to leading experts discuss guideline-directed strategies for mutational analysis and monitoring response when treating patients with chronic-phase chronic myeloid leukaemia with approved tyrosine kinase inhibitors. The expert(s) This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Takeda Development Center Americas, Inc. Jointly provided by Partners for Advancing Clinical Education and touchIME. For further information, visit our websites: www.touchHAEMATOLOGY.com www.touchONCOLOGY.com

Duration:00:39:56

Ask host to enable sharing for playback control

Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs

3/4/2026
touchPANEL DISCUSSION for touchONCOLOGY and touchRESPIRATORY Listen to leading experts discuss the role of antibody–drug conjugates (ADCs) in NSCLC with brain metastases, including the latest clinical trial evidence, practical approaches to patient selection and treatment sequencing alongside local CNS therapies, and the evolving pipeline of investigational ADCs. The expert(s) This touchPODCAST is for HCPs only outside of the UK. This activity is funded by an independent medical education grant fromAstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchONCOLOGY.com www.touchRESPIRATORY.com

Duration:00:39:32

Ask host to enable sharing for playback control

The bare necessities of hyperphagia in Prader–Willi syndrome: Expert insights on recognition and management

2/27/2026
touchEXPERT FOCUS for touchENDOCRINOLOGY Listen to a series of short interviews with paediatric endocrinologist Dr Ashley Shoemaker as she discusses the clinical manifestations and pathophysiology of Prader–Willi syndrome (PWS), with a focus on hyperphagia by exploring the spectrum across the lifespan of PWS and shares best practices for managing PWS-related hyperphagia within a multidisciplinary framework. The expert: This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Soleno Therapeutics. The activity is jointly provided by Partners for Advancing Clinical Education (Partners) and touchIME. For further information, visit our website: www.touchENDOCRINOLOGY.com

Duration:00:35:27

Ask host to enable sharing for playback control

Evolving paradigms in PNH management: Interpreting the latest data

2/25/2026
touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY Listen to a panel of leading experts as they explore the latest advances in PNH pathophysiology, diagnostic approaches and therapeutic strategies, including data from ASH 2025, with practical insights for contemporary clinical practice. The experts: This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Alexion Pharma GmbH. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

Duration:00:45:06

Ask host to enable sharing for playback control

Diagnosis, multidisciplinary monitoring and individualized management in LOPD

1/21/2026
touchCASES for touchNEUROLOGY, touchCARDIO, touchENDOCRINOLOGY and touchRESPIRATORY Listen to two experts as they discuss three cases illustrating the heterogeneous, multisystem nature of late-onset Pompe disease (LOPD). They examine key decision points from recognizing early clinical clues and confirming diagnosis to optimizing enzyme replacement therapy (ERT), monitoring progression and coordinating multidisciplinary, patient-centred care. The experts: This activity is for HCPs outside of the USA. This activity is supported by an independent educational grant from Amicus Therapeutics UK LTD. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchNEUROLOGY.com, touchCARDIO.com, touchENDOCRINOLOGY.com or touchRESPIRATORY.com

Duration:00:34:31

Ask host to enable sharing for playback control

Unlocking the possibilities of BCMA-directed therapies in RRMM: Latest perspectives from IMS and ASH 2025

1/21/2026
touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice. Overview Clinical themes The internationally renowned multiple myeloma expert faculty This touchPODCAST is for HCPs outside of the USA. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

Duration:01:01:07

Ask host to enable sharing for playback control

Evolving strategies in low-grade serous ovarian cancer: Applying the evidence to optimize patient care

1/14/2026
touchEXPERT FOCUS for touchONCOLOGY Listen to insights from Dr Kathleen Moore on the pathophysiology and molecular features of low-grade serous ovarian cancer (LGSOC) and how it differs from other ovarian cancers. She also discusses evidence-based treatment options and sequencing, as well as practical considerations relating to administration and side-effect management. The expert: This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Verastem, Inc. The activity is jointly provided by Partners for Advancing Clinical Education and touchIME. For further information visit our website: www.touchONCOLOGY.com

Duration:00:42:34

Ask host to enable sharing for playback control

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

1/5/2026
touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Paul Hofman, University Côte d’Azur, Nice, France. This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd. This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

Duration:01:35:56

Ask host to enable sharing for playback control

Managing cytopenias: The path to transfusion independence for patients with myelofibrosis

12/5/2025
touchIN CONVERSATION for touchHAEMATOLOGY The presence of anaemia and/or thrombocytopenia complicates the management of patients with myelofibrosis (MF). Listen to expert haematologists consider the burden of cytopenias in patients with MF and discuss strategies to reduce transfusion dependence, improve splenomegaly and personalize treatment with JAK inhibitors. The experts This touchPODCAST is for HCPs outside of the USA. This activity is supported by an independent medical education grant from GSK. This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP). touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com

Duration:00:36:46

Ask host to enable sharing for playback control

Innovations and advances in CML: Focus on navigating early-line options and maintaining quality of life

11/19/2025
touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY Listen to a series of short interviews with three leading experts who provide their insights into early-line management of chronic myeloid leukaemia and the impact on quality of life. The experts: This activity is for healthcare professionals outside of the USA and UK. This independent medical education is supported by Novartis and is provided by touchIME. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

Duration:00:38:34

Ask host to enable sharing for playback control

Breakthroughs in treating NSCLC: Targeting KRAS

11/19/2025
touchTALKS for touchONCOLOGY Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making. The expert This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com

Duration:00:31:11

Ask host to enable sharing for playback control

HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers

11/18/2025
touchEXPERT FOCUS for touchONCOLOGY Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA. The experts This touchPODCAST is for HCPs outside of the UK This activity is supported by an independent educational grant from Jazz Pharmaceuticals. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com

Duration:00:45:43

Ask host to enable sharing for playback control

Delivering state-of-the-art care for GEP-NETs: Evidence-based strategies for PRRT

11/18/2025
touchPANEL DISCUSSION for touchONCOLOGY and touchENDOCRINOLOGY Listen to a panel of leading experts discuss the optimal management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), with a focus on peptide receptor radionuclide therapy (PRRT). The faculty provide their insights on the current state of the art, the evolving role of PRRT in GEP-NET treatment, and recent data with existing and emerging PRRT agents. The faculty will also consider future developments in this field, including personalized approaches to PRRT, and how they might impact clinical care. The experts: This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from ITM Isotope Technologies Munich SE. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchONCOLOGY.com and www.touchENDOCRINOLOGY.com

Duration:00:49:06

Ask host to enable sharing for playback control

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

11/5/2025
touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd. This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: add url

Duration:01:06:08

Ask host to enable sharing for playback control

Eyeing better outcomes in diabetic macular oedema: Clinical insights on the evolving role of corticosteroids

10/30/2025
touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen to a series of interviews with two medical retina specialists and a biomarker expert who will provide their insights into the pathophysiology of diabetic macular oedema (DMO), including the inflammatory mechanisms of disease and how they may impact treatment. The faculty will also consider the clinical utility of optical coherence tomography (OCT) imaging biomarkers and emerging evidence on the evolving role of corticosteroids in the management of DMO. The experts: This touchPODCAST is for HCPs outside of the UK and USA. This activity is funded by an independent medical education grant from Alimera Sciences Europe Ltd. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchOPHTHALMOLOGY.com

Duration:00:34:18

Ask host to enable sharing for playback control

Diagnosis and treatment of patients with Lennox–Gastaut syndrome

10/23/2025
touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of experts in epilepsy as they discuss how to promptly and accurately diagnose and manage Lennox–Gastaut syndrome (LGS). Moderated by a leading European expert, this episode brings together faculty from the Gulf region and Japan, as they explore diagnostic approaches in their regions, before sharing their unique regional perspectives and real-world experience in caring for patients with LGS. The experts Prof. Nicola Specchio: Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy Dr Raidah Al-Baradie: King Fahad Specialist Hospital, Dammam, Saudi Arabia Dr Taoufik Alsaadi: American Center for Neurology, Abu Dhabi, Dubai, UAE Prof. Eiji Nakagawa: National Center of Neurology and Psychiatry, Tokyo, Japan Prof. Hideo Yamanouchi: Saitama Medical University, Saitama, Japan Chapters This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical educational grant from Jazz Pharmaceuticals. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit: touchneurologyime.org/

Duration:00:56:20

Ask host to enable sharing for playback control

Updates in hypertrophic cardiomyopathy care: Bridging the current treatment gaps with emerging novel therapies

10/20/2025
touchEXPERT FOCUS for touchCARDIO Listen to short interviews with two expert cardiologists discussing the role of current and emerging therapeutic classes that aim to address the unmet needs of patients with hypertrophic cardiomyopathy. The faculty will review current therapeutic approaches for managing obstructive versus nonobstructive hypertrophic cardiomyopathy to highlight existing gaps in patient care. They will then discuss the latest data for emerging therapeutic classes and consider how they may address patients’ unmet needs in the future. The expert(s) This touchPODCAST is for HCPs, cardiology nurse specialists and pharmacists with a primary focus on Europe and a secondary focus on the USA. This activity is supported by an independent medical educational grant from Cytokinetics, Inc. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchcardio.com/

Duration:00:31:54

Ask host to enable sharing for playback control

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

10/14/2025
touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd. This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: add url

Duration:00:30:17